N17465 / Onchilles Pharma - LARVOL DELTA

N17465, a systemically deliverable elastase, attenuates tumorigenesis and stimulates anti-tumor immunity (AACR 2024) - "Altogether, our data demonstrate that N17465 selectively kills cancer cells, produces durable responses in mice, induces favorable immunology and synergies with checkpoint inhibitors in pre-clinical models. Its ability to maintain enzymatic activity in blood following systemic delivery, selectively kill a wide range of cancer cells, and stimulate anti-tumor immunity warrants further investigation of this unique therapeutic modality across a wide range of solid tumors."

IO biomarker • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • ELANE • FAS

Onchilles Pharma Presents at AACR 2024 New Preclinical Data for N17350 and N17465 Demonstrating the Potential for Potent and Tumor-Selective Treatment (Businesswire) - "Onchilles Pharma...announced today the presentation of new preclinical data for systemically delivered N17465 in an oral presentation...at the American Association for Cancer Research (AACR) Annual Meeting 2024....N17465 induced immunogenic cell death (ICD) markers in cancer cell lines and patient ovarian cancer cells and was also well tolerated by non-cancer cells. Systemically delivered N17465 produced tumor-free mice in a murine CT26 colon cancer model and induced a favorable immune profile. N17465 also exhibited efficacy across a range of xenograft models spanning human lung, colon, breast, and prostate cancer, as well as ovarian cancer patient-derived CDX models."

Preclinical • Breast Cancer • Colon Cancer • Lung Cancer • Ovarian Cancer • Prostate Cancer